4.8 Article

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

期刊

SCIENCE
卷 369, 期 6504, 页码 718-+

出版社

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.abc6027

关键词

-

资金

  1. Fonds IMMUNOV, for Innovation in Immunopathology
  2. Institut National de la Sante et de la Recherche Medicale (INSERM)
  3. Agence National de la Recherche as part of the Investment for the Future program [ANR-10-IAHU-01]
  4. Agence National de la Recherche (ANR-flash Covid19 AIROCovid)
  5. Agence National de la Recherche (ANR-flash Covid19 CoVarImm)
  6. Institut Imagine M.D.-Ph.D. fellowship program by Fondation Bettencourt Schueller
  7. FAST Foundation (French Friends of Sheba Tel Hashomer Hospital)
  8. EUR G.E.N.E. program of the Universite de Paris - French Government through its Investments for the Future program [ANR-17-EURE-0013, IdEx ANR-18-IDEX-0001]
  9. Agence National de la Recherche as part of the Investment for the Future program (Laboratoire d'Excellence Milieu Interieur) [ANR-10-LABX-69-01]
  10. Institut Pasteur
  11. Agence Nationale de la Recherche (ANR) [ANR-17-EURE-0013] Funding Source: Agence Nationale de la Recherche (ANR)

向作者/读者索取更多资源

Coronavirus disease 2019 (COVID-19) is characterized by distinct patterns of disease progression that suggest diverse host immune responses. We performed an integrated immune analysis on a cohort of 50 COVID-19 patients with various disease severity. A distinct phenotype was observed in severe and critical patients, consisting of a highly impaired interferon (IFN) type I response (characterized by no IFN-beta and low IFN-alpha production and activity), which was associated with a persistent blood viral load and an exacerbated inflammatory response. Inflammation was partially driven by the transcriptional factor nuclear factor-kappa B and characterized by increased tumor necrosis factor-alpha and interleukin-6 production and signaling. These data suggest that type I IFN deficiency in the blood could be a hallmark of severe COVID-19 and provide a rationale for combined therapeutic approaches.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据